Published in Cell on June 26, 1992
Genetic pathways to primary and secondary glioblastoma. Am J Pathol (2007) 9.27
mdm2 expression is induced by wild type p53 activity. EMBO J (1993) 8.01
The first 30 years of p53: growing ever more complex. Nat Rev Cancer (2009) 8.00
Genomic instability--an evolving hallmark of cancer. Nat Rev Mol Cell Biol (2010) 7.11
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev (1999) 6.87
A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A (2001) 6.25
Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev (2000) 5.90
DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev (1997) 5.76
Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A (1998) 5.74
The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev (2000) 5.72
p53 ubiquitination: Mdm2 and beyond. Mol Cell (2006) 5.57
Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol (1993) 5.31
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev (2000) 5.16
Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer (2009) 5.12
Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J (1998) 4.98
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A (2006) 4.68
The MDM2 gene amplification database. Nucleic Acids Res (1998) 4.64
Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol (2003) 4.61
Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol (2010) 4.19
The gadd and MyD genes define a novel set of mammalian genes encoding acidic proteins that synergistically suppress cell growth. Mol Cell Biol (1994) 4.15
MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J (1996) 4.13
Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol (2004) 4.08
ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev (2001) 4.06
Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A (1992) 4.06
Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol (1993) 4.04
P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci U S A (1999) 3.78
Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A (1994) 3.76
Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc Natl Acad Sci U S A (2000) 3.74
MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer (2013) 3.60
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol (2009) 3.47
Molecular interaction map of the mammalian cell cycle control and DNA repair systems. Mol Biol Cell (1999) 3.41
Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer (2014) 3.37
Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol Cell Biol (2004) 3.31
The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. Mol Cell Biol (1994) 3.16
Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci U S A (1999) 3.13
Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J (1998) 3.12
Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J (2004) 3.10
Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol Cell Biol (1994) 3.05
Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci U S A (1999) 2.89
mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol (1996) 2.78
Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc Natl Acad Sci U S A (1995) 2.76
p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev (2000) 2.74
Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol (2000) 2.72
Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains. Proc Natl Acad Sci U S A (1996) 2.66
Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol (1995) 2.62
A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A (2009) 2.61
Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J (2004) 2.59
p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev (2009) 2.57
Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci U S A (1995) 2.56
The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol (1993) 2.55
BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci U S A (1998) 2.50
DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMBO J (1999) 2.50
MdmX protects p53 from Mdm2-mediated degradation. Mol Cell Biol (2000) 2.50
A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell (2010) 2.47
Loss of function of def selectively up-regulates Delta113p53 expression to arrest expansion growth of digestive organs in zebrafish. Genes Dev (2005) 2.44
Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol Med (1995) 2.44
Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev (1997) 2.37
The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription. Mol Cell Biol (1993) 2.37
SUMO-specific protease 2 is essential for modulating p53-Mdm2 in development of trophoblast stem cell niches and lineages. PLoS Biol (2008) 2.35
Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway. PLoS Biol (2006) 2.35
Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev (2006) 2.35
p53 Research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol (2010) 2.34
Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex. Mol Cell Biol (2000) 2.34
mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol (2003) 2.32
A plausible model for the digital response of p53 to DNA damage. Proc Natl Acad Sci U S A (2005) 2.32
Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci U S A (1996) 2.30
Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J Cell Biol (2006) 2.27
The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev (2010) 2.27
Increased activity of p53 in senescing fibroblasts. Proc Natl Acad Sci U S A (1995) 2.27
A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res (1995) 2.23
Btf, a novel death-promoting transcriptional repressor that interacts with Bcl-2-related proteins. Mol Cell Biol (1999) 2.22
The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J (2006) 2.21
Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci U S A (2006) 2.20
Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol (2001) 2.19
p53-catalyzed annealing of complementary single-stranded nucleic acids. EMBO J (1993) 2.16
Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. Mol Cell Biol (2001) 2.15
The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer (1994) 2.14
MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBO J (2003) 2.13
C-terminal ubiquitination of p53 contributes to nuclear export. Mol Cell Biol (2001) 2.09
The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J (2007) 2.07
Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res (2008) 2.04
Hypoxia links ATR and p53 through replication arrest. Mol Cell Biol (2002) 2.03
Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol (2006) 2.02
The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc Natl Acad Sci U S A (1993) 2.01
Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A (1998) 2.00
MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol (1999) 2.00
miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress. EMBO J (2011) 1.98
Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol Cell Biol (2001) 1.96
Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J (1997) 1.96
Oxidative stress in ischemic brain damage: mechanisms of cell death and potential molecular targets for neuroprotection. Antioxid Redox Signal (2011) 1.96
Physical and functional interaction between WT1 and p53 proteins. Proc Natl Acad Sci U S A (1993) 1.96
Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. Am J Pathol (1997) 1.95
The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol Med (1996) 1.94
Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination. Mol Cell Biol (2000) 1.93
Activation and activities of the p53 tumour suppressor protein. Br J Cancer (2001) 1.90
Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res (2009) 1.87
Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO J (1997) 1.85
Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J (2003) 1.85
Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J (1996) 1.82
Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A (2006) 1.82
The sequence of the human genome. Science (2001) 101.55
Surfing the p53 network. Nature (2000) 35.36
Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci U S A (1999) 35.16
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell (1990) 20.60
Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays. Nat Biotechnol (2000) 15.79
Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell (1979) 14.05
Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science (1990) 12.88
The p53 proto-oncogene can act as a suppressor of transformation. Cell (1989) 11.67
The p53-mdm-2 autoregulatory feedback loop. Genes Dev (1993) 11.19
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science (1996) 9.48
Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell (1982) 9.27
Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol (1988) 6.44
Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev (1991) 6.30
Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol Cell Biol (1981) 6.02
Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev (1994) 5.68
p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci U S A (1994) 5.49
Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol (1993) 5.31
Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev (2000) 5.04
Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J (1998) 4.98
Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature (1984) 4.86
Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol (1989) 4.63
Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res (2001) 4.50
DNA replication in SV40 infected cells. I. Analysis of replicating SV40 DNA. J Mol Biol (1970) 4.49
Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ (1990) 4.32
Gain of function mutations in p53. Nat Genet (1993) 4.19
Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A (1992) 4.06
Mapping genetic elements of Epstein-Barr virus that facilitate extrachromosomal persistence of Epstein-Barr virus-derived plasmids in human cells. Mol Cell Biol (1985) 4.03
p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev (1991) 4.01
Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol (1998) 3.99
The process of infection with bacteriophage phiX174. XXV. Studies with bacteriophage phiX174 mutants blocked in progeny replicative form DNA synthesis. J Mol Biol (1969) 3.87
P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci U S A (1999) 3.78
Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc Natl Acad Sci U S A (2000) 3.74
WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A (1998) 3.73
A cellular oncogene (c-Ki-ras) is amplified, overexpressed, and located within karyotypic abnormalities in mouse adrenocortical tumour cells. Nature (1983) 3.56
Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors. Cell (1984) 3.56
Isolation and characterization of polyoma host range mutants that replicate in nullipotential embryonal carcinoma cells. Proc Natl Acad Sci U S A (1981) 3.55
Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev (1999) 3.41
Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature (1995) 3.39
Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cell Biol (1983) 3.39
Adenovirus early region 1B 58,000-dalton tumor antigen is physically associated with an early region 4 25,000-dalton protein in productively infected cells. J Virol (1984) 3.38
Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev (1992) 3.37
Functions of the MDM2 oncoprotein. Cell Mol Life Sci (1999) 3.35
The SV40 A gene product is required for the production of a 54,000 MW cellular tumor antigen. Virology (1979) 3.33
DNA-binding proteins specific for cells infected by adenovirus. Nat New Biol (1973) 3.30
Thermolabile DNA binding proteins from cells infected with a temperature-sensitive mutant of adenovrius defective in viral DNA synthesis. J Virol (1975) 3.29
Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A (1992) 3.27
Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals. Proc Natl Acad Sci U S A (2001) 3.16
The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. Mol Cell Biol (1994) 3.16
An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A (2001) 3.14
The p53MH algorithm and its application in detecting p53-responsive genes. Proc Natl Acad Sci U S A (2002) 3.11
Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain (1991) 3.07
Identification of the p53 protein domain involved in formation of the simian virus 40 large T-antigen-p53 protein complex. J Virol (1986) 3.04
Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines. Mol Cell Biol (1987) 3.01
Conversion of the lac repressor into an allosterically regulated transcriptional activator for mammalian cells. Mol Cell Biol (1990) 3.00
Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res (1994) 2.98
Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci U S A (1999) 2.89
mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol (1996) 2.78
Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc Natl Acad Sci U S A (1995) 2.76
p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev (2000) 2.74
Monoclonal antibodies which recognize native and denatured forms of the adenovirus DNA-binding protein. Virology (1983) 2.69
WISP-1 is a Wnt-1- and beta-catenin-responsive oncogene. Genes Dev (2000) 2.67
A monoclonal antibody detecting the adenovirus type 5-E1b-58Kd tumor antigen: characterization of the E1b-58Kd tumor antigen in adenovirus-infected and -transformed cells. Virology (1982) 2.65
Identification and mapping of Epstein-Barr virus early antigens and demonstration of a viral gene activator that functions in trans. J Virol (1986) 2.64
A comparison of the biological activities of wild-type and mutant p53. FASEB J (1993) 2.49
Characterization of monoclonal antibodies and polyclonal immune sera directed against human cytomegalovirus virion proteins. Virology (1984) 2.48
The p53 functional circuit. J Cell Sci (2001) 2.46
Mechanism by which fiber antigen inhibits multiplication of type 5 adenovirus. J Virol (1967) 2.44
Nuclear export of the E1B 55-kDa and E4 34-kDa adenoviral oncoproteins mediated by a rev-like signal sequence. EMBO J (1997) 2.44
Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol Med (1995) 2.44
Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene (1999) 2.43
Identification and characterization of an immunologically conserved adenovirus early region 11,000 Mr protein and its association with the nuclear matrix. J Mol Biol (1982) 2.36
Induced alpha helix in the VP16 activation domain upon binding to a human TAF. Science (1997) 2.35
A chimeric mammalian transactivator based on the lac repressor that is regulated by temperature and isopropyl beta-D-thiogalactopyranoside. Proc Natl Acad Sci U S A (1991) 2.35
Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci U S A (1996) 2.30
Deoxyribonucleic acid replication in simian virus 40-infected cells. II. Detection and characterization of simian virus 40 pseudovirions. J Virol (1970) 2.30
DNA replication in SV40-infected cells. IX. The inhibition of a gap-filling step during discontinuous synthesis of SV40 DNA. Virology (1973) 2.27
Purification of complexes of nuclear oncogene p53 with rat and Escherichia coli heat shock proteins: in vitro dissociation of hsc70 and dnaK from murine p53 by ATP. Mol Cell Biol (1988) 2.25
Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood (1999) 2.22
Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell (1990) 2.20
The amino acid sequence of murine p53 determined from a c-DNA clone. Virology (1984) 2.15
Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene (1993) 2.11
Targeting p53 as a general tumor antigen. Proc Natl Acad Sci U S A (1995) 2.09
Deoxyribonucleic acid replication in simian virus 40-infected cells. 3. Comparison of simian virus 40 lytic infection in three different monkey kidney cell lines. J Virol (1970) 2.09
Control of group C meningococcal disease in Australian aboriginal children by mass rifampicin chemoprophylaxis and vaccination. Lancet (1995) 2.06
Identification and characterization of a p53 homologue in Drosophila melanogaster. Proc Natl Acad Sci U S A (2000) 2.04
The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc Natl Acad Sci U S A (1993) 2.01
Diagnostic value of cervical discography in the management of cervical discogenic pain. Conn Med (2000) 1.99
Evidence for non-spliced SV40 RNA in undifferentiated murine teratocarcinoma stem cells. Nature (1979) 1.99
Identification of a mouse homolog of the human BTEB2 transcription factor as a beta-catenin-independent Wnt-1-responsive gene. Mol Cell Biol (2001) 1.98
Mutant p53 proteins bind DNA abnormally in vitro. Oncogene (1991) 1.96
The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol Med (1996) 1.94
A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene (2007) 1.92
Interaction of a nuclear factor with the polyomavirus enhancer region. Proc Natl Acad Sci U S A (1986) 1.89
Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev (1996) 1.86
SV40 large tumor antigen can regulate some cellular transcripts in a positive fashion. Cell (1982) 1.85
Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer (2013) 1.85
Nuclear localization is essential for the activity of p53 protein. Oncogene (1991) 1.83
Oestrogen receptors and prognosis in early breast cancer. Lancet (1979) 1.83
Functional limits of oriP, the Epstein-Barr virus plasmid origin of replication. J Virol (1989) 1.82